Improved Immunotherapeutic Dosing Regimens And Combinations Thereof

Abstract

The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of immunotherapeutic agents e.g. CTLA-4 antagonists such as 3pilimumab or Tremelimumab in combination with one or more chemotherapeutic agents in cancer patients.


Claims
Download PDF
Document Preview
Document History
  • Publication: Nov 24, 2011
  • Application: May 16, 2011
    WO US 2011/0036626 W
  • Priority: Mar 15, 2011
    US US 201161452841 P
  • Priority: May 17, 2010
    US US 34533410 P

Download Citation


Sign in to the Lens

Feedback